HRP20210724T1 - Supstituirani derivati indolina kao inhibitori replikacije denga virusa - Google Patents
Supstituirani derivati indolina kao inhibitori replikacije denga virusa Download PDFInfo
- Publication number
- HRP20210724T1 HRP20210724T1 HRP20210724TT HRP20210724T HRP20210724T1 HR P20210724 T1 HRP20210724 T1 HR P20210724T1 HR P20210724T T HRP20210724T T HR P20210724TT HR P20210724 T HRP20210724 T HR P20210724T HR P20210724 T1 HRP20210724 T1 HR P20210724T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydrogen
- chlorine
- carbon
- compound
- image
- Prior art date
Links
- 206010012310 Dengue fever Diseases 0.000 title claims 4
- 208000025729 dengue disease Diseases 0.000 title claims 4
- 208000001490 Dengue Diseases 0.000 title 1
- 229940123627 Viral replication inhibitor Drugs 0.000 title 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 33
- 150000002431 hydrogen Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000000460 chlorine Substances 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- -1 pentafluorosulfanyl Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (11)
1. Spoj s formulom (I), uključujući bilo koji njegov stereokemijski izomerni oblik,
[image]
naznačen time što
A je
[image]
pri čemu
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je pentafluorsulfanil, R5 je vodik, Z je ugljik, i R6 je vodik; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetil, R5 je vodik, Z je ugljik, i R6 je metil; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetil, R5 je fluor, Z je ugljik, i R6 je vodik; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetoksi, R5 je vodik, Z je ugljik, i R6 je metil; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetoksi, R5 je fluor, Z je ugljik, i R6 je vodik; ili
R1 je fluor, R2 je metoksi, R3 je vodik, A je (a-1), R4 je trifluormetoksi, R5 je vodik, Z je ugljik, i R6 je vodik; ili
R1 je klor, R2 je vodik, R3 je deuterij, A je (a-1), R4 je trifluormetoksi, R5 je vodik, Z je ugljik, i R6 je vodik; ili
R1 je klor, R2 je -OCH2CH2OH, R3 je vodik, A je (a-1), R4 je trifluormetoksi, R5 je vodik, Z je ugljik, i R6 je vodik; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetil, R5 je metoksi, Z je dušik, i R6 je odsutan; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-2), i R4 je trifluormetil; ili
R1 je klor, R2 je vodik, R3 je vodik, A je (a-1), R4 je trifluormetiltio, R5 je vodik, Z je ugljik, i R6 je vodik;
ili njegova farmaceutski prihvatljiva sol, solvat ili polimorf.
2. Spoj prema patentnom zahtjevu 1 naznačen time što A je (a-1).
3. Spoj prema patentnom zahtjevu 1 naznačen time što A je (a-2).
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3 naznačen time što navedeni spoj ima (+) specifičnu rotaciju.
5. Spoj prema patentnom zahtjevu 1 naznačen time što se navedeni spoj bira od:
[image]
[image]
[image]
[image]
6. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 5 zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili nosača.
7. Farmaceutski pripravak prema patentnom zahtjevu 6 naznačen time što sadrži drugi ili daljnji aktivni sastojak.
8. Farmaceutski pripravak prema patentnom zahtjevu 7 naznačen time što je drugi ili daljnji aktivni sastojak antivirusno sredstvo.
9. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 5 naznačen time što je za uporabu kao lijek.
10. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 5 se koristi u liječenju virusne infekcije Denga groznicom i za prevenciju ili liječenje bolesti povezane s virusnom infekcijom Denga groznicom.
11. Spoj s formulom (I) za uporabu u skladu s patentnim zahtjevom 10 naznačen time što je virusna infekcija Denga groznicom infekcija virusima soja DENV-1, DENV-2, DENV-3 ili DENV-4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172247 | 2017-05-22 | ||
| PCT/EP2018/063029 WO2018215316A1 (en) | 2017-05-22 | 2018-05-18 | Substituted indoline derivatives as dengue viral replication inhibitors |
| EP18729051.5A EP3630724B1 (en) | 2017-05-22 | 2018-05-18 | Substituted indoline derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210724T1 true HRP20210724T1 (hr) | 2021-10-15 |
Family
ID=58745159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210724TT HRP20210724T1 (hr) | 2017-05-22 | 2021-05-10 | Supstituirani derivati indolina kao inhibitori replikacije denga virusa |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11053196B2 (hr) |
| EP (1) | EP3630724B1 (hr) |
| JP (1) | JP7179773B2 (hr) |
| KR (1) | KR102625991B1 (hr) |
| CN (1) | CN110753682B (hr) |
| AR (1) | AR111820A1 (hr) |
| AU (1) | AU2018274101C1 (hr) |
| BR (1) | BR112019024311A2 (hr) |
| CA (1) | CA3061026C (hr) |
| CL (1) | CL2019003309A1 (hr) |
| CO (1) | CO2019013042A2 (hr) |
| CR (1) | CR20190531A (hr) |
| DK (1) | DK3630724T3 (hr) |
| EA (1) | EA039702B1 (hr) |
| EC (1) | ECSP19083621A (hr) |
| ES (1) | ES2884157T3 (hr) |
| HR (1) | HRP20210724T1 (hr) |
| HU (1) | HUE054379T2 (hr) |
| IL (1) | IL270727B2 (hr) |
| LT (1) | LT3630724T (hr) |
| MX (1) | MX2019013878A (hr) |
| PE (1) | PE20200342A1 (hr) |
| PH (1) | PH12019502577A1 (hr) |
| SI (1) | SI3630724T1 (hr) |
| TW (1) | TWI771420B (hr) |
| UA (1) | UA125970C2 (hr) |
| UY (1) | UY37741A (hr) |
| WO (1) | WO2018215316A1 (hr) |
| ZA (1) | ZA201907713B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| MA52976A (fr) * | 2018-06-19 | 2021-04-28 | Novartis Ag | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations |
| WO2020139991A1 (en) | 2018-12-27 | 2020-07-02 | Agios Pharmaceuticals, Inc. | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| WO2023278564A1 (en) | 2021-07-02 | 2023-01-05 | Mirati Therapeutics, Inc. | Aminopyridine-based mta-cooperative prmt5 inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| CA2308443A1 (en) | 1997-10-27 | 1999-05-06 | Michael Lyle Denney | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| US6861504B2 (en) | 2001-05-03 | 2005-03-01 | Cbr, Inc. | Compounds and methods for the modulation of CD154 |
| WO2003050295A2 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| JP2008526980A (ja) | 2005-01-14 | 2008-07-24 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルス感染症を治療するためのインドール誘導体 |
| US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| CA2726985A1 (en) | 2008-06-03 | 2009-12-10 | Siga Technologies, Inc. | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| CN102160233B (zh) | 2008-08-22 | 2013-12-04 | 日本化药株式会社 | 染料敏化的光电转换器件 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| US7948798B1 (en) | 2009-07-22 | 2011-05-24 | Marvell International Ltd. | Mixed multi-level cell and single level cell storage device |
| PT2523951E (pt) | 2010-01-15 | 2015-09-14 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
| EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER |
| JP5716205B2 (ja) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法 |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| SG11201702463YA (en) | 2014-10-01 | 2017-04-27 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| NO2721243T3 (hr) | 2014-10-01 | 2018-10-20 | ||
| ME03344B (me) | 2014-10-01 | 2019-10-20 | Janssen Pharmaceuticals Inc | Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa |
| JOP20150335B1 (ar) * | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3370698B1 (en) | 2015-11-03 | 2022-01-26 | Zoetis Services LLC | Sol-gel polymer composites and uses thereof |
| BR112018068538B1 (pt) | 2016-03-31 | 2023-12-12 | Takeda Pharmaceutical Company Limited | Composto, medicamento, e, uso de um composto |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
| EA039392B1 (ru) | 2016-04-01 | 2022-01-21 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способ лечения рака с применением замещенного аминопуринового соединения |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| IL296966A (en) | 2016-04-01 | 2022-12-01 | Amgen Inc | Chimeric flt-3 receptors and methods of using them |
| JOP20170069B1 (ar) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN113150170A (zh) | 2016-04-01 | 2021-07-23 | 凯德药业股份有限公司 | 嵌合受体及其方法和用途 |
| UA123912C2 (uk) | 2016-04-01 | 2021-06-23 | Басф Се | Біциклічні сполуки |
| TW202313671A (zh) | 2016-04-01 | 2023-04-01 | 美商凱特製藥公司 | 嵌合抗原和ｔ細胞受體及使用方法 |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
-
2018
- 2018-05-18 PE PE2019002416A patent/PE20200342A1/es unknown
- 2018-05-18 MX MX2019013878A patent/MX2019013878A/es unknown
- 2018-05-18 WO PCT/EP2018/063029 patent/WO2018215316A1/en active Application Filing
- 2018-05-18 TW TW107116922A patent/TWI771420B/zh not_active IP Right Cessation
- 2018-05-18 EA EA201992784A patent/EA039702B1/ru unknown
- 2018-05-18 HU HUE18729051A patent/HUE054379T2/hu unknown
- 2018-05-18 IL IL270727A patent/IL270727B2/en unknown
- 2018-05-18 EP EP18729051.5A patent/EP3630724B1/en active Active
- 2018-05-18 SI SI201830306T patent/SI3630724T1/sl unknown
- 2018-05-18 CA CA3061026A patent/CA3061026C/en active Active
- 2018-05-18 CN CN201880033731.2A patent/CN110753682B/zh active Active
- 2018-05-18 US US16/614,715 patent/US11053196B2/en active Active
- 2018-05-18 KR KR1020197037345A patent/KR102625991B1/ko active IP Right Grant
- 2018-05-18 UA UAA201912061A patent/UA125970C2/uk unknown
- 2018-05-18 ES ES18729051T patent/ES2884157T3/es active Active
- 2018-05-18 JP JP2019564452A patent/JP7179773B2/ja active Active
- 2018-05-18 LT LTEP18729051.5T patent/LT3630724T/lt unknown
- 2018-05-18 DK DK18729051.5T patent/DK3630724T3/da active
- 2018-05-18 CR CR20190531A patent/CR20190531A/es unknown
- 2018-05-18 AU AU2018274101A patent/AU2018274101C1/en active Active
- 2018-05-18 BR BR112019024311-9A patent/BR112019024311A2/pt active Search and Examination
- 2018-05-22 AR ARP180101352A patent/AR111820A1/es unknown
- 2018-05-22 UY UY0001037741A patent/UY37741A/es unknown
-
2019
- 2019-11-18 CL CL2019003309A patent/CL2019003309A1/es unknown
- 2019-11-18 PH PH12019502577A patent/PH12019502577A1/en unknown
- 2019-11-21 ZA ZA2019/07713A patent/ZA201907713B/en unknown
- 2019-11-22 EC ECSENADI201983621A patent/ECSP19083621A/es unknown
- 2019-11-22 CO CONC2019/0013042A patent/CO2019013042A2/es unknown
-
2021
- 2021-05-10 HR HRP20210724TT patent/HRP20210724T1/hr unknown
- 2021-05-28 US US17/334,432 patent/US11702387B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210724T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20211102T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20210942T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20231018T1 (hr) | Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| IL269370A (en) | Chemicals, preparations and methods for the treatment and prevention of orthopedic virus infections and related diseases | |
| HRP20200138T1 (hr) | Kombinirana formulacija dva antivirusna spoja | |
| NZ610715A (en) | Antiviral compounds and methods | |
| MY154683A (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| PH12020551709A1 (en) | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | |
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| GB0612423D0 (en) | Therapeutic agents | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| EA201591702A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
| CY1114892T1 (el) | Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση | |
| MX2021004182A (es) | Inhibidores macrocíclicos de endonucleasa de la gripe. | |
| HRP20200332T1 (hr) | Modifikator eksenatida i njegova primjena | |
| EA202092159A1 (ru) | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| EA202092814A1 (ru) | Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства |